Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation

C. E. Freise, S. M. Kang, S. Feng, A. Posselt, K. Hirose, R. Hirose, P. Stock

Research output: Contribution to journalArticle

Abstract

Introduction Steroid avoidance is possible in simultaneous pancreas-kidney transplantation with the use of newer immunosuppressive agents and induction therapy. We undertook a retrospective consecutive case review of patients treated at a university tertiary referral center. Methods Medical records of 44 consecutive patients receiving a pancreas-kidney transplant from November 2000 to September 2002 were reviewed. The immunosuppression protocol used in this series of patients consisted of thymoglobulin induction, combined with mycophenolate mofetil, tacrolimus, and sirolimus for maintenance immunosuppression. Steroids were used only while thymoglobulin was given and were typically discontinued by postoperative week 1. Main outcome measures included graft and patient survival rates, rejection rates of the kidney or pancreas, infection rates, and surgical complication rates. Results All 44 patients received a kidney-pancreas transplant with systemic venous anastomosis and enteric drainage of the pancreas. Patient kidney, and pancreas survival rates were 95.6%, 93.2%, and 88.7%, respectively. Biopsy-proven pancreas rejection rates at 1 and 6 months posttransplant were 2.3% and 2.3%. Kidney rejection rates at 1 and 6 months were 2.3% and 4.6%. Reasons for patient loss included one death from sepsis and one cardiovascular death. Reasons for kidney loss besides death included a thrombotic microangiopathy. Reasons for pancreas loss included three thromboses, one mild rejection/infection, and one duodenal segment leak with infection. All patients who have been free of rejection have been off steroids for the duration of follow-up. Conclusions Newer immunosuppression protocols without maintenance steroids are possible with minimal rejection in the first 3 months and equivalent patient and graft survival rates compared with earlier protocols utilizing steroids. The potential beneficial long-term impact of steroid avoidance will require further study.

Original languageEnglish (US)
Pages (from-to)1067-1068
Number of pages2
JournalTransplantation Proceedings
Volume36
Issue number4
DOIs
StatePublished - May 2004
Externally publishedYes

Fingerprint

Pancreas Transplantation
Kidney Transplantation
Immunosuppression
Steroids
Maintenance
Pancreas
Kidney
Survival Rate
Graft Survival
Infection
Thrombotic Microangiopathies
Mycophenolic Acid
Transplants
Tacrolimus
Sirolimus
Immunosuppressive Agents
Tertiary Care Centers
Medical Records
Drainage
Sepsis

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. / Freise, C. E.; Kang, S. M.; Feng, S.; Posselt, A.; Hirose, K.; Hirose, R.; Stock, P.

In: Transplantation Proceedings, Vol. 36, No. 4, 05.2004, p. 1067-1068.

Research output: Contribution to journalArticle

Freise, C. E. ; Kang, S. M. ; Feng, S. ; Posselt, A. ; Hirose, K. ; Hirose, R. ; Stock, P. / Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. In: Transplantation Proceedings. 2004 ; Vol. 36, No. 4. pp. 1067-1068.
@article{b51c30d10c86422daf5aae4c306e415e,
title = "Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation",
abstract = "Introduction Steroid avoidance is possible in simultaneous pancreas-kidney transplantation with the use of newer immunosuppressive agents and induction therapy. We undertook a retrospective consecutive case review of patients treated at a university tertiary referral center. Methods Medical records of 44 consecutive patients receiving a pancreas-kidney transplant from November 2000 to September 2002 were reviewed. The immunosuppression protocol used in this series of patients consisted of thymoglobulin induction, combined with mycophenolate mofetil, tacrolimus, and sirolimus for maintenance immunosuppression. Steroids were used only while thymoglobulin was given and were typically discontinued by postoperative week 1. Main outcome measures included graft and patient survival rates, rejection rates of the kidney or pancreas, infection rates, and surgical complication rates. Results All 44 patients received a kidney-pancreas transplant with systemic venous anastomosis and enteric drainage of the pancreas. Patient kidney, and pancreas survival rates were 95.6{\%}, 93.2{\%}, and 88.7{\%}, respectively. Biopsy-proven pancreas rejection rates at 1 and 6 months posttransplant were 2.3{\%} and 2.3{\%}. Kidney rejection rates at 1 and 6 months were 2.3{\%} and 4.6{\%}. Reasons for patient loss included one death from sepsis and one cardiovascular death. Reasons for kidney loss besides death included a thrombotic microangiopathy. Reasons for pancreas loss included three thromboses, one mild rejection/infection, and one duodenal segment leak with infection. All patients who have been free of rejection have been off steroids for the duration of follow-up. Conclusions Newer immunosuppression protocols without maintenance steroids are possible with minimal rejection in the first 3 months and equivalent patient and graft survival rates compared with earlier protocols utilizing steroids. The potential beneficial long-term impact of steroid avoidance will require further study.",
author = "Freise, {C. E.} and Kang, {S. M.} and S. Feng and A. Posselt and K. Hirose and R. Hirose and P. Stock",
year = "2004",
month = "5",
doi = "10.1016/j.transproceed.2004.04.017",
language = "English (US)",
volume = "36",
pages = "1067--1068",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation

AU - Freise, C. E.

AU - Kang, S. M.

AU - Feng, S.

AU - Posselt, A.

AU - Hirose, K.

AU - Hirose, R.

AU - Stock, P.

PY - 2004/5

Y1 - 2004/5

N2 - Introduction Steroid avoidance is possible in simultaneous pancreas-kidney transplantation with the use of newer immunosuppressive agents and induction therapy. We undertook a retrospective consecutive case review of patients treated at a university tertiary referral center. Methods Medical records of 44 consecutive patients receiving a pancreas-kidney transplant from November 2000 to September 2002 were reviewed. The immunosuppression protocol used in this series of patients consisted of thymoglobulin induction, combined with mycophenolate mofetil, tacrolimus, and sirolimus for maintenance immunosuppression. Steroids were used only while thymoglobulin was given and were typically discontinued by postoperative week 1. Main outcome measures included graft and patient survival rates, rejection rates of the kidney or pancreas, infection rates, and surgical complication rates. Results All 44 patients received a kidney-pancreas transplant with systemic venous anastomosis and enteric drainage of the pancreas. Patient kidney, and pancreas survival rates were 95.6%, 93.2%, and 88.7%, respectively. Biopsy-proven pancreas rejection rates at 1 and 6 months posttransplant were 2.3% and 2.3%. Kidney rejection rates at 1 and 6 months were 2.3% and 4.6%. Reasons for patient loss included one death from sepsis and one cardiovascular death. Reasons for kidney loss besides death included a thrombotic microangiopathy. Reasons for pancreas loss included three thromboses, one mild rejection/infection, and one duodenal segment leak with infection. All patients who have been free of rejection have been off steroids for the duration of follow-up. Conclusions Newer immunosuppression protocols without maintenance steroids are possible with minimal rejection in the first 3 months and equivalent patient and graft survival rates compared with earlier protocols utilizing steroids. The potential beneficial long-term impact of steroid avoidance will require further study.

AB - Introduction Steroid avoidance is possible in simultaneous pancreas-kidney transplantation with the use of newer immunosuppressive agents and induction therapy. We undertook a retrospective consecutive case review of patients treated at a university tertiary referral center. Methods Medical records of 44 consecutive patients receiving a pancreas-kidney transplant from November 2000 to September 2002 were reviewed. The immunosuppression protocol used in this series of patients consisted of thymoglobulin induction, combined with mycophenolate mofetil, tacrolimus, and sirolimus for maintenance immunosuppression. Steroids were used only while thymoglobulin was given and were typically discontinued by postoperative week 1. Main outcome measures included graft and patient survival rates, rejection rates of the kidney or pancreas, infection rates, and surgical complication rates. Results All 44 patients received a kidney-pancreas transplant with systemic venous anastomosis and enteric drainage of the pancreas. Patient kidney, and pancreas survival rates were 95.6%, 93.2%, and 88.7%, respectively. Biopsy-proven pancreas rejection rates at 1 and 6 months posttransplant were 2.3% and 2.3%. Kidney rejection rates at 1 and 6 months were 2.3% and 4.6%. Reasons for patient loss included one death from sepsis and one cardiovascular death. Reasons for kidney loss besides death included a thrombotic microangiopathy. Reasons for pancreas loss included three thromboses, one mild rejection/infection, and one duodenal segment leak with infection. All patients who have been free of rejection have been off steroids for the duration of follow-up. Conclusions Newer immunosuppression protocols without maintenance steroids are possible with minimal rejection in the first 3 months and equivalent patient and graft survival rates compared with earlier protocols utilizing steroids. The potential beneficial long-term impact of steroid avoidance will require further study.

UR - http://www.scopus.com/inward/record.url?scp=2942687875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942687875&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2004.04.017

DO - 10.1016/j.transproceed.2004.04.017

M3 - Article

C2 - 15194370

AN - SCOPUS:2942687875

VL - 36

SP - 1067

EP - 1068

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 4

ER -